Revenue

With Talya Nevo-Hacohen retiring, veteran Darrin Smith takes the helm as CIO. How will his vision shape Sabra's portfolio in a dynamic healthcare REIT market?

Activist investor YZi Labs accuses CEA Industries of entrenchment after it adopted a 'poison pill,' escalating a battle over board control and crypto strategy.

KIOXIA's new BG7 SSDs use breakthrough BiCS FLASH Gen 8 and CBA tech to deliver major speed and power efficiency gains for the next generation of PCs.

As media giants face a fragmented ad landscape, Operative's new AOS Services Platform aims to unify linear and digital revenue with an AI-driven core.

A new health initiative aims to fight chronic disease with personalized nutrition. But can data from your body truly fix a broken food system?

Lucid crushed its 2025 production goals with a huge Q4 surge, but a widening gap between cars built and sold raises serious questions about demand.

At CES 2026, Ubicept's new toolkit promises to let AI see clearly in the dark and at high speed, ushering in a new era for robotics and autonomous cars.

As it marks 32 years, Alexandria Real Estate Equities proves its resilience, dominating the market it created amid industry-wide headwinds.

BridGene Biosciences adds Nobel winner Dr. Bruce Beutler to its board, gaining immense credibility for its mission to create drugs for intractable diseases.

A new initiative is tackling the fear and distrust that costs patients their health and the system trillions. Is 'cognitive safety' healthcare's next frontier?

Founder Chuck Cohn pours millions more into his ed-tech firm, a bold move that signals deep confidence despite a slumping stock and cautious analysts.

Fintech firm Movemint's rebrand signals a major shift for banks, focusing on embedded finance and personalized experiences to drive measurable growth.

With a hot obesity pipeline and a key neurology asset, Nxera Pharma's J.P. Morgan talk is a crucial test of its plan for global leadership.

William Healey, a 25-year veteran, takes the helm as IAAO's 2026 President, guiding the future of global property valuation amid technological change.

With a $257M war chest and a veteran team, BlossomHill will showcase its innovative pipeline for lung cancer and leukemia at the pivotal JPM conference.

With surging revenue for its cholesterol drugs and new guideline backing, Esperion outlines its strategy for profitability and pipeline expansion.

AUKEY unveils a 200W GaN charging hub with retractable cables and 25W Qi2, leading a new lineup designed to declutter the modern professional's desk.

With stunning clinical data for its miv-cel therapy, Kyverna is set to outline a new era for autoimmune treatment at the J.P. Morgan conference.

Post-merger, Kepler Fusion unveils its strategy for commercializing compact, aneutronic fusion reactors, betting on a distributed 'Power-as-a-Service' model.

With 35 years at the company, new CEO John Baylouny plans to accelerate R&D and expand into new markets, building on a period of strong growth.